LAUSR

Society for Publication of Acta Dermato-Venereologica Bullous pemphigoid (BP) is a rare acquired autoimmune skin disease characterized by urticarial rash, pruritus and blistering. BP histopathology demonstrates a subepidermal cleft with an eosinophil-rich inflammatory infiltrate. Direct immunofluorescence (DIF) from perilesional skin usually shows a linear band of IgG and/or C3 deposits along the epidermal–dermal junction. Indirect immunofluorescence (IIF) allows the detection of serum IgG autoantibodies targeting the basement membrane zone (BMZ), primarily against antigen-BP180 and/or antigen-BP230 (1, 2). Druginduced BP is usually associated with oral therapies (3) and has been recognized as an infrequent therapy-related autoimmune skin toxicity of immune checkpoint blockade (ICB) (4–6). Drug-induced BP is extremely uncommon in association with targeted therapy for melanoma (TT; e.g. BRAFand MEK-inhibitors) (5, 7). We report here 3 cases of patients with metastatic BRAFV600 mutated melanoma that developed eosinophilrich BP-like eruptions during TT.